Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P35813

UPID:
PPM1A_HUMAN

ALTERNATIVE NAMES:
Protein phosphatase 2C isoform alpha; Protein phosphatase IA

ALTERNATIVE UPACC:
P35813; B5BU11; J3KNM0; O75551

BACKGROUND:
The enzyme Protein phosphatase 1A, recognized alternatively as Protein phosphatase 2C isoform alpha and Protein phosphatase IA, is integral to regulating key signaling pathways. It negatively regulates TGF-beta signaling through specific dephosphorylation of SMAD2 and SMAD3, facilitating their separation from SMAD4 and concluding the signaling process. It also plays a critical role in dephosphorylating PRKAA1 and PRKAA2 and terminating TNF-alpha-induced NF-kappa-B activation by deactivating IKBKB/IKKB.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Protein phosphatase 1A could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.